Lab
MDX Labs LLC
MDX Labs LLC was paid $397K by Medicaid between Apr 2021 and Jun 2023, across 33 billing codes. Its largest line is U0004, 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by cms-2020-01-r — 76% of everything it billed.
33Billing provider infoMDX LABS LLC
HENDERSON, NV 89014
HENDERSON, NV 89014
33aNPI1871177998assigned 05/06/2021
33bProvider typeClinical Medical Laboratory
28Total paid$397K
24GClaims29,831
24DCodes billed33
24AFirst – last monthApr 2021 – Jun 2023
Compared with peers
Next to other Clinical Medical Laboratory providers in Nevada
Rank by total paid#15 of 31
Median peer was paid$269K
This provider vs. median1.5×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2021 | 4,034 | $68K | |
| 2022 | 18,988 | $265K | |
| 2023 | 6,809 | $63K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| U0004 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by cms-2020-01-r | 76% | 8,212 | 4,853 | $303K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | 7.1% | 7,873 | 4,617 | $28K |
| G2023 | Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | 6.5% | 8,203 | 4,851 | $26K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 6.1% | 782 | 296 | $24K |
| 86481 | 1.3% | 383 | 297 | $5K | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 363 | 153 | $2K |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 323 | 262 | $1K |
| 87522 | Neg quan hep c or qual rna | <1% | 156 | 136 | $1K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 113 | 88 | $957.84 |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 137 | 122 | $570.00 |
| 80061 | Lipid panel | <1% | 315 | 258 | $543.90 |
| 80053 | Comprehensive metabolic panel | <1% | 338 | 279 | $421.16 |
21 more codes
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 115 | $402.20 |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 103 | $354.32 |
| 86780 | <1% | 135 | $339.51 | |
| 86696 | <1% | 108 | $336.60 | |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 345 | $299.21 |
| 82607 | <1% | 137 | $293.00 | |
| 82728 | <1% | 136 | $265.05 | |
| 86695 | <1% | 133 | $256.50 | |
| 82746 | <1% | 109 | $255.76 | |
| 84439 | <1% | 169 | $235.64 | |
| 87340 | <1% | 167 | $215.05 | |
| 80050 | General health panel | <1% | 13 | $208.57 |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 193 | $199.58 |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 177 | $182.03 |
| 83735 | <1% | 133 | $130.25 | |
| 83540 | <1% | 135 | $110.85 | |
| 81001 | <1% | 221 | $99.72 | |
| 82747 | <1% | 18 | $35.46 | |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 19 | $25.66 |
| 85610 | <1% | 39 | $13.45 | |
| 86803 | <1% | 28 | $9.74 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialBRIGGS, DANIEL (PRESIDENT)